[Advances in roles of Parabacteroides distasonis and its regulation by traditional Chinese medicines]
- PMID: 39701697
- DOI: 10.19540/j.cnki.cjcmm.20240611.708
[Advances in roles of Parabacteroides distasonis and its regulation by traditional Chinese medicines]
Abstract
Parabacteroides distasonis is a gram-negative bacterium initially isolated from a clinical specimen in the 1930s. The strain was re-classified to form the new genus Parabacteroides in 2006. P. distasonis can regulate intestinal barrier function and plays a key role in immune response and metabolic regulation of bodies. Traditional Chinese medicine(TCM) is closely related to the intestinal microbiota. Polysaccharides, saponins, and other ingredients of TCM can treat diseases by interacting with P. distasonis, but the specific mechanisms underlying these processes are still unclear, requiring further exploration. This study reviewed the roles and related mechanisms of P. distasonis in inflammatory-immune diseases, metabolic diseases, cardiovascular disease, neuropsychiatric diseases, cancer, and other diseases and summarized the relevant research results of TCM to prevent and treat diseases by regulating P. distasonis. This study provides a reference for subsequent exploration of P. distasonis and research on the interaction between TCM and intestinal microbiota.
Keywords: Parabacteroides distasonis; intestinal microbiota; pharmacological effects; traditional Chinese medicine.
Similar articles
-
Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health.Gut Microbes. 2021 Jan-Dec;13(1):1922241. doi: 10.1080/19490976.2021.1922241. Gut Microbes. 2021. PMID: 34196581 Free PMC article. Review.
-
Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut.mBio. 2024 Apr 10;15(4):e0007824. doi: 10.1128/mbio.00078-24. Epub 2024 Mar 12. mBio. 2024. PMID: 38470269 Free PMC article.
-
Review of the correlation between Chinese medicine and intestinal microbiota on the efficacy of diabetes mellitus.Front Endocrinol (Lausanne). 2023 Jan 25;13:1085092. doi: 10.3389/fendo.2022.1085092. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36760813 Free PMC article. Review.
-
Targeting regulation of lipid metabolism with polysaccharide of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease: A review.Int J Biol Macromol. 2025 May;306(Pt 3):141660. doi: 10.1016/j.ijbiomac.2025.141660. Epub 2025 Mar 1. Int J Biol Macromol. 2025. PMID: 40032085 Review.
-
Interplay between traditional Chinese medicine polysaccharides and gut microbiota: The elusive "polysaccharides-bond-bacteria-enzyme" equation.Phytother Res. 2024 Sep;38(9):4695-4715. doi: 10.1002/ptr.8284. Epub 2024 Aug 9. Phytother Res. 2024. PMID: 39120443 Review.